Baystate Wealth Management’s Novartis NVS Stock Holding History

Baystate Wealth Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$35.6K	Buy	352 +42	+14%	+$4.05K	﹤0.01%	437
2023 Q3	$31.6K	Buy	310 +50	+19%	+$5.08K	﹤0.01%	402
2023 Q2	$26.3K	Hold	260	–	–	﹤0.01%	421
2023 Q1	$24K	Sell	260 -16	-6%	-$1.4K	﹤0.01%	436
2022 Q4	$25K	Buy	276 +16	+6%	+$1.35K	﹤0.01%	426
2022 Q3	$20K	Hold	260	–	–	﹤0.01%	431
2022 Q2	$22K	Hold	260	–	–	﹤0.01%	438
2022 Q1	$23K	Sell	260 -4	-2%	-$346	﹤0.01%	431
2021 Q4	$23K	Hold	264	–	–	﹤0.01%	448
2021 Q3	$22K	Hold	264	–	–	﹤0.01%	405
2021 Q2	$24K	Sell	264 -255	-49%	-$22.7K	﹤0.01%	370
2021 Q1	$44K	Buy	519 +9	+2%	+$808	﹤0.01%	276
2020 Q4	$48K	Hold	510	–	–	0.01%	253
2020 Q3	$44K	Sell	510 -45	-8%	-$3.9K	0.01%	234
2020 Q2	$48K	Buy	555 +45	+9%	+$3.88K	0.01%	229
2020 Q1	$42K	Sell	510 -115	-18%	-$10.3K	0.01%	206
2019 Q4	$59K	Hold	625	–	–	0.01%	209
2019 Q3	$54K	Buy	625 +115	+23%	+$10.3K	0.01%	197
2019 Q2	$47K	Sell	510 -59	-10%	-$4.99K	0.01%	218
2019 Q1	$40K	Buy	569 +11	+2%	+$883	0.01%	238
2018 Q4	$44K	Hold	558	–	–	0.01%	218
2018 Q3	$42K	Hold	558	–	–	0.01%	225
2018 Q2	$38K	Hold	558	–	–	0.01%	220
2018 Q1	$39K	Hold	558	–	–	0.01%	215
2017 Q4	$44K	Hold	558	–	–	0.01%	212
2017 Q3	$43K	Hold	558	–	–	0.01%	198
2017 Q2	$42K	Sell	558 -670	-55%	-$47.5K	0.01%	197
2017 Q1	$81K	Buy	1,228 +620	+102%	+$41.3K	0.02%	132
2016 Q4	$40K	Buy	+608	New	+$39.4K	0.01%	163
2013 Q3	–	Sell	-642	Closed	-$41K	–	166
2013 Q2	$41K	Buy	+642	New	+$41.8K	0.02%	110

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Baystate Wealth Management's NVS Position: Q4 2023 in Review

Baystate Wealth Management increased its Novartis (NVS) stake by 14% in Q4 2023, buying an estimated $4.05K and bringing the position to 352 shares worth $35.6K. The position accounts for ﹤0.01% of the portfolio, ranked #437.

Baystate Wealth Management first reported a position in NVS in Q2 2013 and has held it in 30 quarters since. The position peaked at $81K in Q1 2017. 1,272 funds tracked by Wall St. Rank hold NVS as of Q4 2023.

Baystate Wealth Management held 352 shares of Novartis worth $35.6K as of Q4 2023.
Baystate Wealth Management bought 42 Novartis shares in Q4 2023, an estimated $4.05K.
Novartis made up ﹤0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #437 holding.
Baystate Wealth Management first reported a position in Novartis in Q2 2013 and has held it in 30 quarters since.
Baystate Wealth Management's Novartis position peaked at $81K in Q1 2017.
1,272 funds tracked by Wall St. Rank held Novartis as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.